TrialFrontiers in immunology2022

A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine.

Isabel Leroux-Roels et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.